Written question asked by Lord Turnberg (Labour) on Monday, 23 November 2015, in the House of Lords. It was due for an answer on Monday, 7 December 2015. It was answered by Lord Prior of Brampton (Conservative) on Tuesday, 1 December 2015 on behalf of the Department of Health.
Muscular Dystrophy: Drugs
- Question
-
To ask Her Majesty’s Government when they expect NICE to publish its opinion about the availability of Translarna for the treatment of patients with Duchene Muscular Dystrophy, following its approval by the European Medicines Agency in July 2014.
- Answer
-
The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance on the clinical and cost effectiveness of drugs and treatments. NICE is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. NICE currently expects to publish its final guidance in February 2016.
The NHS in England is legally required to fund drugs and treatments recommended in NICE highly specialised technology guidance within three months of its final guidance being issued. In the absence of guidance from NICE, it is for commissioners to make decisions on whether to fund medicines based on an assessment of the available evidence.
Secondary information
- Type
- Written question
- Reference
- HL3823
- Session
- 2015-16
- Subjects
- Drugs Muscular dystrophy Ataluren
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2016-07-05 20:14:19 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2015-16/HL3823
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2015-16/HL3823
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2015-16/HL3823